Vaginal yeast infection, or vulvovaginal candidiasis, is a common cause of vaginal irritation. In addition, 12 to 15 percent of men develop symptoms after sexual contact with an infected partner.
Prestige Brands Holdings, Inc. today announced that it has entered into a definitive agreement to acquire Insight Pharmaceuticals Corporation, a marketer and distributor of feminine care and other over-the-counter ("OTC") healthcare products, for $750 million in cash.
Janssen Research & Development, LLC (Janssen) today announced it has received from the U.S. Food and Drug Administration (FDA) a complete response letter regarding its New Drug Application (NDA) for a fixed-dose combination (FDC) of canagliflozin and immediate-release metformin to treat adults with type 2 diabetes.
Researchers have developed a new assay for rapid and sensitive detection of Chlamydia trachomatis, the most common sexually transmitted infection (STI) in humans.
Male circumcision reduces the abundance of bacteria living on the penis and might help explain why circumcision offers men some protection against HIV, according to a study led by the Translational Genomics Research Institute.
The U.S. Food and Drug Administration today approved Invokana (canaglifozin) tablets, used with diet and exercise, to improve glycemic control in adults with type 2 diabetes.
Pfizer Inc. and Ligand Pharmaceuticals Incorporated today announced that the United States Food and Drug Administration (FDA) accepted for review a New Drug Application (NDA) for bazedoxifene/conjugated estrogens (BZA/CE), a potential new medicine for non-hysterectomized women for the treatment of moderate-to-severe vasomotor symptoms (VMS) and vulvar and vaginal atrophy (VVA) associated with menopause, as well as the prevention of postmenopausal osteoporosis.
Pfizer Inc. today announced that the European Medicines Agency (EMA) accepted for review the Marketing Authorization Application (MAA) for bazedoxifene/conjugated estrogens (BZA/CE), a potential new medicine for postmenopausal women with a uterus for the treatment of estrogen deficiency symptoms and treatment of osteoporosis in women at risk of fracture.
According to an NIH-funded Harvard study, an estimated six million women in America suffer from vulvodynia. Despite the astonishingly high number of those affected, the pain is often left misdiagnosed or untreated.
Glen Palmer, PhD, Assistant Professor of Microbiology, Immunology & Parasitology at LSU Health Sciences Center New Orleans, was part of an international research team led by Luigina Romani, MD, at the University of Perugia, that discovered opportunistic fungi like Candida albicans can sense the immune status of host cells and adapt, evading immune system defenses.
Vaginal thrush is one of the most popular topics on NHS Choices website. This common yeast infection affects around 75% (three-quarters) of women at some point. Up to half of these will have thrush more than once.
Researchers are a step closer towards creating a new class of medicines and vaccines to combat drug-resistant and deadly strains of fungal infections, following a new study published today in Proceedings of the National Academy of Sciences.
A new study reveals that just as different soldiers in the field have different jobs, subsets of a type of immune cell that polices the barriers of the body can promote unique and opposite immune responses against the same type of infection.
A new, rapid blood test that could lead to early diagnosis and potentially save the lives of hundreds of thousands of people stricken with fungal meningitis, a leading cause of AIDS-related deaths in developing countries, is getting closer to market with a recent collaboration between the University of Nevada, Reno and Immuno-Mycologics in Oklahoma.
Bayer HealthCare Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration has approved a new oral contraceptive, Beyaz (drospirenone / ethinyl estradiol / levomefolate calcium tablets and levomefolate calcium tablets).
Few women go through life having never suffered from the uncomfortable symptoms of a yeast infection. In fact, nearly 3 in 4 (72 percent) women will experience their first yeast infection before age 25. Furthermore, the incidence of yeast infections is highest among young women ages 18-24, who are new to the category and uncertain about symptoms and available treatment options.
Novo Nordisk Inc. today announced that it has signed an exclusive agreement with Upsher-Smith Laboratories, Inc. to market Vagifem (estradiol vaginal tablets) 10 mcg. Under the terms of the agreement, Upsher-Smith will exclusively market Vagifem 10 mcg to physicians in the U.S. beginning August 2 through the company's existing field sales force.
Women looking for the best method to manage common symptoms of menopause, like hot flashes and night sweats, may not have access to credible information, especially when it comes to understanding their estrogen therapy options. In fact, there are an array of celebrities and authors who are simply not qualified to give medical advice about managing menopause, yet they dominate the internet and media space simply because of their popularity.
Doctors have highlighted potential problems with the breathing system filters used in anaesthesia, including intensive care units, after demonstrating that they don't provide protection from harmful bacteria and yeast when they become wet.
Merck today announced that the U.S. Food and Drug Administration (FDA) has approved DULERA® (mometasone furoate and formoterol fumarate dihydrate) Inhalation Aerosol, a new fixed-dose combination asthma treatment for patients 12 years of age and older. DULERA is not indicated for the relief of acute bronchospasm. DULERA combines an inhaled corticosteroid (mometasone furoate) with a long-acting beta2-agonist (formoterol fumarate).
The National Association of Nurse Practitioners in Women's Health announced the launch of Estrogen Therapy I.Q. a campaign devoted to improving access to credible information about menopause and advances in estrogen therapy.